T he shared tumor-associated Ags (TAAs) 5 that are potential targets of cancer immunotherapy primarily consist of nonmutated self-Ags that are either lineage-specific or overexpressed. Due to immunological tolerance toward these proteins, B cells producing high affinity Abs and T cells expressing high-affinity TCRs are often deleted, making the remaining repertoire relatively unresponsive to active immunization. Furthermore, for those Ags for which self-tolerance is incomplete, the process of tumor development can actively tolerize the remaining T cells (1) . In the absence of an effective endogenous TAA-specific immune repertoire, passive immunization with TAA-specific Abs or T cells may be considered a preferred approach (2) . In line with this, the clinical use of recombinant Abs such as Rituximab that targets CD20 and Trastuzumab that targets Her2/Neu has been a major advance in the treatment of human cancer over the past decade (3) .
Analogous to the transfer of high-affinity Abs, adoptive transfer of exogenous tumor-specific TCRs into endogenous T cells (a process hereafter referred to as TCR gene transfer) might be used to generate T cells directed toward TAAs such as wilms tumor Ag 1 (WT-1) and Preferentially Expressed Ag of Melanoma (PRAME). Like the HER-2/neu protein targeted by Trastuzumab, these Ags are nonmutated proteins that are over expressed by cancer cells, being either leukemic (4) or melanoma cells (5) . Furthermore, for all these proteins, over-expression contributes to cellular transformation, making tumor escape a less likely event (6 -8) . In the present study, we set out to analyze the value of TCR gene transfer in the targeting of this class of tumor-associated Ags in a murine spontaneous tumor model. These experiments assess the feasibility of TCR gene therapy for tumor types for which classical forms of adoptive T cell therapy may be precluded and compare it to the value of active vaccination.
Materials and Methods
Mice C57BL/6 (B6) and transgenic adenocarcinoma of mouse prostate (TRAMP) mice (9) were obtained from the Experimental Animal Department of The Netherlands Cancer Institute. For all experiments, F 1 offspring of B6 ϫ TRAMP mice was used. All animal experiments were performed in accordance with institutional and national guidelines and were approved by the Experimental Animal Committee of The Netherlands Cancer Institute.
Retroviral constructs and retroviral transduction of T cells
The SV40 IV specific TCR ␣-and ␤-chains were cloned by standard procedures from the cytotoxic T lymphocyte clone Y-4. The Y-4 clone was isolated by limiting dilution from CTL-derived from B6 mice immunized with SV40 large T Ag transformed syngeneic kidney cells and has been described previously (10) . A pMX-SV40␣-IRES-SV40␤ vector was generated and used to transfect Phoenix-E packaging cells to generate retrovirus (11) . Mouse splenocytes were modified by retroviral transduction as described previously (12) .
Flow cytometry
Surface TCR expression was measured 24 h post transduction by flow cytometry. Cells were stained with FITC-labeled anti-TCR V␤ 9mAb and PE-labeled anti-TCR V␤ 2, 3, 4, 5.1, 8, 11, and 10b mAb (anti V␤-pool), or with MHC tetramers, in combination with PE-or allophycocyanin-conjugated anti-CD8␣ mAb (all mAbs from BD Pharmingen, except PE-conjugated anti-CD8␣ mAb from Caltag). Propidium iodide (Sigma-Aldrich) was used to select for live cells. For the measurement of Ag-specific T cell responses in peripheral blood, samples were taken at the indicated days post transfer. Following removal of erythrocytes by NH 4 Cl treatment, cells were stained with the above-mentioned Abs and analyzed by flow cytometry. For analysis of SV40-specific T cell responses in spleen and prostate, mice were sacrificed 11 days post vaccination, spleen and prostate tissue were harvested, and single cell suspensions were obtained by macerating tissues through a 40-m nylon cell strainer. Intracellular IFN-␥ staining was performed as previously described (12) . Data acquisition and analysis was done on a FACSCalibur (Becton Dickinson) with FCS Express software (De Novo Software) or CellQuest Pro software (BD Biosciences).
Viral infection
For live influenza A infections, anesthetized mice were infected by intranasal administration of 50 l of HBSS (Life Technologies) containing 1000 PFU of influenza A/WSN/33 (WSN)-SV40(IV) virus (flu-T) (K. Schepers, E. Swart, and T. Schumacher, unpublished data). For vaccinia infections, 1 ϫ 10 5 PFU rVV-ES-IV (rVV-T) was injected i.p (13) .
Histopathology
Tissues were sampled in buffered formalin and stained with H&E. The sections were reviewed with a Zeiss Axioskop2 Plus microscope (Carl Zeiss Microscopy, Jena, Germany) equipped with Plan-Apochroma (ϫ5/ 0.16, ϫ10/0.45, ϫ20/0.60, and ϫ40/0.95) and Plan-Neofluar (ϫ2.5/0.075) objectives. In addition to the objectives, there was an extra enlargement device included in the body of the microscope. Images were captured with a Zeiss AxioCam HRc digital camera and processed with AxioVision 4 software (both from Carl Zeiss Vision). Pathological examination and classification of the prostate gland, coagulation gland, and seminal vesicles was performed blindly, according to The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium (14) .
Immunohistochemistry
Immunohistochemistry was conducted on buffered formalin sections. Sections were preincubated with PBS/4% BSA. For large T immunostaining, sections were stained for 1 h with SV40 pb 101 primary Ab (1/500, Becton Dickinson), followed by a two-step immunoenzymatic procedure. First, biotin labeled goat-anti-mouse immunoglobulins (DakoCytomation, 1/500, 1 h) were applied, followed by HRP-labeled avidin-biotin complex (DakoCytomation, 1 h). AEC (Sigma-Aldrich) was used as a substratechromagen and slides were counterstained with hematoxylin. Images were acquired using an Axiocam HR digital camera and processed with Axiovision 4 software (Carl Zeiss Vision GmbH).
Statistical analysis
To test whether two treatments had the same underlying multinomial (ordered) distribution of type of pathology, a Stratified Wilcoxon-Mann-Whitney U test for ordered categorical responses was used. Two-sided p values are reported.
Results

Development of neoplastic lesions and SV40 expression in TRAMP mice
TRAMP (transgenic adenocarcinoma of mouse prostate) mice express the transforming protein SV40 large T under control of the prostate specific probasin promoter, resulting in the development of prostatic intraepithelial neoplasia (PIN) lesions from 8 to 12 wk of age and carcinomas by 18 wk of age (9; see below). The epithelial cells within prostate areas that undergo pathologic alterations (ranging from atypical hyperplasia to carcinomas) display high SV40 large T expression, as evidenced by immunohistochemistry ( Fig. 1, A-C) . In contrast, SV40 large T expression in prostate cells with a normal morphology is generally below the limit of detection (Fig. 1, A-C) .
The endogenous T cell repertoire of TRAMP mice is tolerant toward SV40 IV at the time neoplastic lesions first develop
Prior work has demonstrated that young (4 -7 wk) male TRAMP mice harbor a residual low avidity T cell repertoire specific for SV40 IV , the immunodominant epitope of the large T oncoprotein. However, from 10 wk of age onwards, this low avidity T cell repertoire is no longer detectable (15) . To corroborate these data, 11-wk old TRAMP mice and nontransgenic littermates were infected with an influenza A strain expressing SV40 IV , the immunodominant epitope of large T (flu-T). Analysis of ex vivo spleen samples (data not shown) or in vitro restimulated T cell cultures revealed that IFN-␥ producing SV40 IV -specific T cells were barely detectable in TRAMP mice, but abundantly present in nontransgenic littermates (Fig. 2, A and B) . Furthermore, when reactivity against the SV40 IV epitope was monitored by MHC tetramer staining, SV40 IV ,-specific T cell responses were also highly reduced in vaccinated TRAMP mice (data not shown). Consistent with prior peptide and DC vaccination studies (15, 16) , these data demonstrate that the endogenous T cell repertoire of TRAMP mice is tolerant toward SV40 IV at the time prostatic lesions first develop. The restricted over-expression of large T in (pre)malignant tissue, its role in transformation, and the induction of tolerance toward large T in TRAMP mice make this protein comparable to tumor-associated self Ags such as WT-1 and PRAME.
TCR gene transfer can be used to create a SV40 IV -reactive T cell compartment that is otherwise absent in TRAMP mice
Prior work has shown that the combination of vaccination with adoptive transfer of T cells modified with a relevant TCR, but not a control TCR, can be used to induce self Ag-specific T cell responses (17) . To assess the value of the induction of self Agreactive T cell responses by TCR gene transfer in the targeting of developing tumors, we isolated an SV40 IV -specific TCR (11) and used this TCR to modify T cells of TRAMP mice. Following retroviral transduction, on average 25-40% of CD8 ϩ T cells expressed the SV40 IV TCR, and these cells produced IFN-␥ upon incubation with the relevant Ag in vitro (Fig. 3, A and B) . To address whether SV40 IV TCR-modified T cells could proliferate upon in vivo Ag encounter, TRAMP mice and as a control B6 mice received an adoptive transfer of 1 ϫ 10 5 SV40 IV TCR CD8 ϩ T cells, followed by an intranasal flu-T infection. Subsequently, TCR-modified T cell responses were monitored by measuring the fraction of T cells expressing one of a set of endogenous V␤ elements together with the V␤ element used by the introduced TCR (17) . Although an endogenous SV40 IV -specific T cell response could not be detected in TRAMP mice (Fig. 2) , SV40 IV -TCR transduced T cells proliferated strongly upon Ag encounter in vivo, as assessed by the emergence of a V␤9
ϩ V␤-pool ϩ T cell population. In line with the notion that the V␤9 ϩ V␤-pool ϩ T cell population consists of TCR-modified T cells, no increase in V␤9 ϩ V␤-pool ϩ T cell numbers was seen in recipients of mock-transduced T cells (Fig. 3C, bottom 
panels). Frequencies of V␤9
ϩ V␤-pool ϩ T cells peaked around day 10 post transfer and subsequently decreased significantly. This contraction of the TCR-modified-specific T cell response is consistent with prior data on the kinetics of endogenous vaccine-induced influenza A-specific T cell responses (18) and is also observed for the endogenous SV40 IV -specific T cell response in B6 mice (data not shown). These experiments show that TCR gene transfer can be used to create a TAA-reactive T cell compartment that is otherwise absent (Fig. 3C) . Interestingly, SV40 IV -TCR transduced T cell responses in TRAMP mice are on average ϳ1.5-2-fold lower than those in B6 controls (average peak T cell response of 8.0 vs 12.9%), suggesting that tolerizing mechanisms may have some impact on the in vivo potential of TCR-modified T cells.
In vivo distribution and function of SV40 IV TCR-modified T cells
To examine the in vivo distribution and function of SV40 IV TCRmodified T cells, prostate glands and spleen samples were isolated from TRAMP and B6 mice at day 11 post vaccination. As expected, V␤9 ϩ V␤-pool ϩ T cells were detected in spleen samples from B6 and TRAMP mice that had received SV40 IV TCR-modified T cells, whereas in control mice that were only vaccinated this population was absent (Fig. 4, A and B) . Furthermore, V␤9
ϩ V␤-pool ϩ T cells were also detected in prostate samples from B6 and TRAMP mice, indicating that homing to the prostate can occur independent of Ag expression. Splenic T cells in B6 and TRAMP mice produced high levels of IFN-␥ after stimulation with the SV40 IV Ag. In TRAMP but not B6 mice, this production was dependent upon adoptive T cell transfer, reflecting that an endogenous SV40 IV -specific T cell repertoire is lacking in TRAMP but not B6 mice. Notably, no substantial Ag-specific IFN-␥ production was detected within prostate tissue, suggesting that the effector function of TCR-modified T cells may possibly be suppressed at this site (Fig. 4) . In cases where multiple types of lesions were detected within one organ, the most severe type was used for scoring. Numbers in bold indicate the number of mice per treatment group that were scored with the indicated lesion type. 
A combination of adoptively transferred SV40 IV TCR-modified T cells and vaccination leads to the long-term suppression of tumor progression in TRAMP mice
To determine the potential impact of adoptive cell therapy (ACT) with TCR-modified T cells on tumor development, a pilot study was performed. A first group of TRAMP mice (n ϭ 5) received vaccination with two SV40 IV -recombinant viruses at week 10 (when PIN lesions are detectable in prostate and coagulation glands in the majority of animals) and at week 16. A second group of mice received vaccination with the same recombinant viruses plus ACT with a small number of TCR-modified T cells (5 ϫ 10 5 ) at the same time points. Two weeks after the second treatment (week 18), mice were sacrificed and analyzed "blindly" for tumor development in prostate glands, coagulation glands, and seminal vesicles. In five of five mice that only received vaccination, microinvasive or invasive carcinomas had developed (Table I) . In marked contrast, microinvasive carcinoma development was only seen in 1 of 5 mice treated by ACT and atypical hyperplasia and PIN were observed in all other mice (Table I ). This first experiment suggested that ACT with TCRmodified T cells may be effective in preventing tumor outgrowth. However, it did not address the long-term effect of ACT with TCR-modified T cells.
To address this issue, a large cohort of mice was treated with the same protocol and then left without further intervention until week 28 (4 mo after the start of ACT/vaccination). Furthermore, to test for a potential effect of vaccination by itself on tumor progression, a third group of mice was included that was left fully untreated (experimental setup in Fig. 5A , analysis of TCR-modified T cell responses in Fig. 5B) . At week 28, mice were sacrificed to analyze tumor development in prostate glands, coagulation glands, and seminal vesicles (Fig. 5, C and D) . In untreated mice, carcinomas developed in all prostate glands (100% of mice) as well as in coagulation glands (60% of mice). In the seminal vesicles, atypical hyperplasia (50% of mice) and adenomas (40% of mice) were detected. Importantly, in mice treated by vaccination only, the incidence of carcinomas in prostate glands (100% of mice) and coagulation glands (55% of mice), and the incidence of adenomas in the seminal vesicles (67% of mice) was not reduced to any measurable extent ( p ϭ 0.9152, Wilcoxon-Mann-Whitney U test). However, when mice received the same vaccination protocol in combination with infusion of SV40 IV -TCR-modified TRAMP T cells, the incidence of carcinomas and adenomas was substantially reduced. In both prostate and coagulation glands, only premalignant lesions were detected in the majority of mice (73 and 64% of mice, respectively). In the seminal vesicles, no abnormalities were detected in 10 of 11 mice (Fig. 5, C and D) .
These data show in a spontaneous tumor model that the combination of TCR gene transfer and vaccination significantly suppresses tumor progression ( p Ͻ 0.0001) and that this effect is long lasting (months upon ACT). Notably, the low-grade lesions that are still detected in tissue sections of mice that were treated by TCR gene therapy remain large T-positive (Fig. 5E, lower left  panel) . In a recent study that showed that vaccination of 8-wk-old TRAMP mice against prostate stem cell Ag can lead to the longterm suppression of tumor development, low-grade lesions were also still detectable in treated mice (19) . However, in this case, the remaining lesions were largely Ag negative. To provide a possible explanation for the persistence of low-grade lesions in the current setting, in which an Ag essential for tumor growth is targeted, we analyzed SV40 IV -specific T cell responses of 28 wk old TRAMP mice treated by TCR gene therapy. Interestingly, this analysis revealed that SV40 IV TCR-modified T cells were barely detectable at this time point in ex vivo spleen samples and could not be expanded in in vitro T cell cultures (data not shown). These data suggest that the prolonged presence of TCR-modified T cells in an Ag-bearing host may lead to deletion. Previous studies in TRAMP mice have demonstrated that both deletion and mechanisms of nondeletional tolerance can impede prostate tumor specific T cell responses (15, 20 -23) . Future studies will be required to determine which mechanisms of tolerance induction can impair the long-term function of adoptively transferred SV40 IV TCR-modified T cells in TRAMP mice.
To directly test whether multiple T cell infusions are required for the long-term suppression of tumor progression, TRAMP mice received either a single cycle of TCR-modified T cell transfer/ vaccination at week 10, or two cycles of TCR-modified T cell transfer/vaccination at week 10 and 16. In both groups of mice, tumor progression was significantly ( p Ͻ 0.01 and p Ͻ 0.001 for one and two cycle groups, respectively) inhibited as compared with recipients of vaccination only. Thus, while there is a (nonsignificant; p ϭ 0.2166) trend toward an increased antitumor effect in mice receiving two cycles of ACT, a single cycle of ACT at week 10 can greatly reduce prostate carcinoma development in the following 4 mo (Fig. 6, A and B) .
Concomitant vaccination is an essential requirement for the suppression of prostate carcinoma by adoptively transferred SV40 IV TCR-modified T cells in TRAMP mice
The above data demonstrate that the combination of vaccination with TCR-modified T cell transfer suppresses tumor outgrowth. However, these experiments do not address whether vaccination is in fact required to achieve this effect. To address this issue, a group of TRAMP mice received two adoptive transfers of SV40 IV TCRmodified T cells at weeks 10 and 16 without further vaccination.
Analysis of V␤9
ϩ V␤-pool ϩ T cell responses in peripheral blood of these animals showed that frequencies of TCR-modified T cells stayed close to background in the absence of vaccination (Fig. 6C) . In line with the observation that vaccination is essential to drive expansion of the TCR-modified T cell pool, tumor progression was not measurably affected by the sole transfer of TCR-modified T cells (Fig. 6D) .
Discussion
Approaches for adoptive T cell therapy of human cancer can be divided into two broad categories based on the use of either allogeneic or of autologous T cells. In allogeneic T cell therapy, as exemplified by donor lymphocyte infusions for patients with chronic myeloid leukemia, the infused T cells can recognize polymorphic epitopes expressed by tumor cells as truly foreign Ags, and thus with high avidity (24) . The very high response rate seen after donor lymphocyte infusions treatment (Ͼ50% for patients with relapsed chronic myeloid leukemia; Ref. 25) underscores the clinical value of T cells that can recognize tumor-associated Ags with such high avidity. However, the requirement for an allogeneic hematopoietic stem cell transplant, plus the frequent development of graft-vs-host-disease, due to T cell recognition of polymorphic Ags expressed by other cell types, form two very substantial limitations of allogeneic T cell therapy. Autologous T cell therapy, by means of infusion of ex vivo expanded patient-derived tumor infiltrating lymphocytes (TILs), has a substantial clinical effect in patients with metastatic melanoma, with an objective response rate of ϳ50% (26 -28) . Autologous T cell therapy is not complicated by the development of graft-vs-host-disease, however, it is restricted to those patient groups for which tumor-infiltrating lymphocytes can be isolated. Specifically, while melanoma-reactive T cell responses can be observed rather frequently, for most other tumor types, the detection of T cell infiltrates with a clear potential for tumor recognition is a rare event.
A comparison of the advantages and disadvantages of allogeneic and autologous T cell therapy suggests that the adoptive transfer of T cells that are autologous, but do express high affinity tumor specific TCRs would be an attractive approach, and this has been the goal of efforts to generate redirected T cells by TCR gene transfer (29) . Following a series of in vitro analyses, the in vivo function of TCR gene-modified T cells has been established in mouse models (12, 17, 30, 31) . Furthermore, a recent phase I clinical trial in patients with metastatic melanoma has demonstrated that the transfer of TCR modified T cells is clinically feasible and that the resultant cells show long-term engraftment in some patients (32) . Although the objective response rate in this trial has been low, this study provided the first evidence that, at least for a tumor type that was previously shown to be responsive to TIL treatment, TCR gene therapy is a realistic option.
The goals of the current study were two-fold: first, to establish whether TCR gene therapy could be developed into a realistic option for tumor types for which TIL transfer is not feasible and second, to make such an assessment in a spontaneous tumor model rather than a transplantable tumor model. The latter issue is of some importance as immunogenicity of unknown neo-Ags that have been introduced or have accumulated during in vitro growth can severely complicate the interpretation of immunological interventions in transplantable tumor models (33) . In addition, the aberrant interaction of newly injected tumor cells with the surrounding stroma, and the draining of injected tumor cells to the secondary lymphoid organs may also lead to an over-interpretation of the efficacy of immunotherapeutic intervention (34) . In the spontaneous tumor model that was used in this study, the numbers of endogenous T cells specific for the tumor-associated epitope that is targeted are close to background levels at the age tumor development is first seen (Ref. 15 ; Fig. 2 ), thereby representing a T cell target Ag for which TIL transfer appears to be precluded. Within this model we show that, whereas vaccination or TCR gene transfer by itself is entirely without effect, the combination of vaccination with TCR gene transfer is highly synergistic. These data directly demonstrate the potential of TCR modified T cells to target tumor types for which classical T cell therapy with autologous tumor-specific T cells has not been possible. As TCRs for Ags such as p53 (35) , WT-1 (31), PRAME (N. Rufer, C. Melief, and T. Schumacher, unpublished data), and murine double minute-2 (36) have been isolated, clinical assessment of such therapies can be expected in the coming years.
It seems reasonable to expect that to obtain strong T cell responses in such trials, (at least) three ingredients will be required. First, it should be feasible to generate a sufficient number of autologous gene-modified T cells for infusion. As the current data demonstrate that the infusion of a small number of gene modified T cells (1-5 ϫ 10 5 of gene-modified T cells; which equals ϳ1% of the total CD8 ϩ T cell compartment) suffices to delay tumor progression, this is unlikely to pose the major problem in future clinical tests. It may, however, be important to ensure that the infused gene-modified T cells have not undergone terminal differentiation (37) .
Second, the sole infusion of TCR gene-modified T cells without further treatment is insufficient for the generation of robust tumorspecific T cell responses (Fig. 6 ). Therefore, a clinically acceptable strategy to promote the expansion of TCR gene-modified T cells is required. Although in the current manuscript, in vivo expansion is achieved by vaccination, host conditioning regimens that have originally been developed for TIL therapy may prove equally or even more effective in this respect (M. de Witte, A. Jorritsma, A. Kaiser, M. van den Boom, M. Dokter, G. Bendle, J. Haanen, and T. Schumacher, unpublished observations). The development of effective strategies to promote in vivo activation of the TCR-modified T cells also appear to be essential to prevent the tolerization of infused TCR-modified T cell populations. In the current study, SV40 IV -TCR transduced T cell responses directly after infusion were on average ϳ1.5-2-fold lower in TRAMP mice than in B6 controls. More importantly, when TCR-modified T cell responses in TRAMP mice were examined months after transfer, reactivity was highly limited. These data are consistent with the notion that the long-term presence of self Ag-reactive T cells in an Ag-bearing host can lead to progressive tolerization (20, 21, 38) and strategies to prevent such tolerization will be valuable.
Third, a collection of (publicly available) high affinity T cell receptors for a series of tumor-associated Ags will need to be created. Biotechnological platforms for TCR isolation may perhaps best be designed by analogy with platforms for recombinant Ab isolation. Specifically, Muromonab-CD3, the first mAb registered for clinical use, was obtained by vaccination of mice and immunogenicity of this fully murine Ab and other Abs of mouse origin has limited their clinical application (39) . To avoid the immunogenicity of mouse Abs in clinical use, increasingly sophisticated approaches for the generation of mAbs with a partial or fully human sequence have been developed in subsequent years, eventually resulting in the creation of mouse strains transgenic for the unrearranged human Ig loci (40) . By analogy to the use of these hIg mouse models for the generation of human Abs against human self-Ags, mouse models that carry the human TCR loci should be of substantial value. Human TCRs obtained from such models may then be used to produce a tumor-reactive T cell repertoire by modification of pre-existing patient derived T cells, or, in the more distant future, such cells may be generated from scratch, through in vitro differentiation of TCR modified T cells from hematopoietic stem cells (41) (42) (43) .
